{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

An observational, cross-sectional survey to assess role of mucolytics in routine clinical practice

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

General Questions
  1. Number of patients with mucus hypersecretion you come across every month *

  2. Amongst all the patients with mucus hypersecretion, which pathology has the highest number of patients? *

  3. How often upper respiratory tract infections are associated with mucus hypersecretion? *

  4. How much percentage of patients with Chronic obstructive pulmonary disease have mucus hypersecretion? *

  5. FEV1 decline in patients with mucus hypersecretion in COPD, how commonly it is seen in your practice? *
  6. Do you agree that chronic mucus hypersecretion in COPD patients increases the risk of mortality? *

  7. Do you agree that chronic mucus hypersecretion worsens the quality of life in COPD patients? *

  8. Do you agree that chronic mucus hypersecretion increases exacerbations in COPD patients? *

  9. Do you agree that chronic mucus hypersecretion increases the risk of hospitalisations in COPD patients? *

  10. Do you agree that mucus hypersecretion should be a therapeutic target in all COPD subjects (i.e. subjects with and without chronic cough and sputum production)? *

  11. How much percentage of patients with asthma have mucus hypersecretion? *

  12. How much percentage of patients with cystic fibrosis have mucus hypersecretion? *

  13. How much percentage of patients with bronchiectasis have mucus hypersecretion? *

  14. Which other conditions in your clinical practice are associated with mucus hypersecretion? *
  15. What criteria do you use to assess the severity of mucus hypersecretion in your patients? *

  16. What criteria do you consider most important when selecting muco-active agents for managing mucus hypersecretion in patients with respiratory illnesses, such as COPD? (Select all that apply) *

  17. Is only physical rehabilitation sufficient for patients with mucus hypersecretion? *

  18. Which muco-active agent do you prefer for treating mucus hypersecretion in these conditions from widely available options? *
    19. Disease condition Preferred muco active agents
    COPD
    Asthma
    Cystic fibrosis
    Bronchiectasis
  19. How often do you consider switching muco-active agents or adjusting dosages based on patient feedback? *

  20. What is the routine protocol of prescribing mucoactive agents in patients of COPD in your practice? (Initiation of treatment, follow up) *
  21. What is the routine protocol of prescribing mucoactive agents in patients of asthma in your practice? (Initiation of treatment, follow up) *
  22. What is the routine protocol of prescribing mucoactive agents in patients of bronchiectasis in your practice? (Initiation of treatment, follow up) *
  23. What is the routine protocol of prescribing mucoactive agents in patients of cystic fibrosis in your practice? (Initiation of treatment, follow up) *
  24. What additional therapies do you commonly combine with muco-active agents in treating mucus hypersecretion? *

  25. Which antibiotics do you commonly prescribe for patients with mucus hypersecretion? (Select all that apply) *

  26. Which clinical benefit with mucolytics is seen most commonly? (Select all that apply) *

  27. How would you rate the effectiveness of Acebrophylline + N-Acetylcysteine compared to other mucoregulators? *

  28. For how long acebrophylline+ N-Acetylcysteine combination is given in COPD patients? *

  29. For how long acebrophylline+ N-Acetylcysteine combination is given in asthma patients? *

  30. For how long acebrophylline+ N-Acetylcysteine combination is given in cystic fibrosis patients? *

  31. For how long acebrophylline+ N-Acetylcysteine combination is given in patients with upper respiratory tract infections? *
  32. What patient demographics have shown the most improvement with this combination therapy?*
  33. Have you observed any differences in treatment response between various patient demographics (age, gender, comorbidities) when using Acebrophylline + N-Acetylcysteine? *

  34. Based on your clinical experience, which muco-active agent has shown the most significant impact on reducing exacerbations in patients?*
  35. Which muco-active agent do you believe has the least side effects while providing effective management of mucus hypersecretion? *
  36. Do you think that combining muco-active agents enhances patient-related outcomes compared to using a single agent? *

  37. How do you typically monitor the effectiveness of muco-active therapy in your patients? (Select all that apply) *

  38. Please provide any additional comments or insights regarding the management of mucus hypersecretion and muco-active therapies. *
  39. What additional resources or support do you believe would be beneficial for improving the management of mucus hypersecretion in your practice? (Select all that apply) *

  40. Do you consider chest physiotherapy in your patients of COPD with mucus hypersecretion? *

  41. What importance change is required in guidelines for the management of mucus hypersecretion? *